肺纤维化全球视角:流行病学、地区差异与诊疗差距
本文从全球视角综述肺纤维化,涵盖其作为多种间质性肺疾病共同结局的病理基础。文章重点讨论不同地区的流行病学差异、诊疗资源缺口及未来方向。内容涉及特发性间质性肺炎、自身免疫相关及暴露相关等分类。
要点
- 肺纤维化以肺实质胶原沉积为特征,导致肺容积减少和弥散功能下降。
- 吸烟、感染、吸入性损伤、药物和环境暴露等均可触发肺纤维化。
- 间质性肺疾病可分为纤维化型和非纤维化型,也可按临床行为分类。
核心结论
- 肺纤维化是多种肺损伤因素触发级联反应后胶原沉积于肺实质的共同结局。
- 作为临床实体,肺纤维化指一组统称为间质性肺疾病的疾病群中发生的纤维化。
研究设计与样本
- 本文为叙述性综述,从全球视角整合肺纤维化的分类、流行病学及地区差异。
主要发现
- 肺纤维化可导致肺容积丧失、限制性通气障碍和弥散能力降低。
- 间质性肺疾病按病因可分为特发性、自身免疫性、暴露相关、伴囊肿或气腔填充型及结节病。
关键数值与推荐
- 间质性肺疾病可按纤维化与否分为纤维化型和非纤维化型。
- 间质性肺疾病也可按疾病行为分为可逆性自限型和不可逆进展型。
临床怎么用
- 临床识别肺纤维化需关注吸烟、环境暴露、感染及药物等潜在触发因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction Pulmonary fibrosis (PF) is marked by collagen deposition in the lung parenchyma causing a loss of lung volume, restricted lung ventilation and reduced diffusion capacity. 1 Various lung insults, such as tobacco smoking, infections, inhalational injury, radiation, drug use, persistent inflammation due to autoimmunity or environmental exposures and others, may trigger a cascade of events that culminate in PF. 2 However, as a specific clinical entity, ‘pulmonary fibrosis’ refers to lung fibrosis that occurs in a group of disorders that are commonly known as interstitial lung diseases (ILDs). 3–6 ILDs may be fibrotic or non-fibrotic ( figure 1 ). 7 They can be categorised into idiopathic interstitial pneumonias (IIPs), autoimmune ILDs, exposure-related ILDs, ILDs with cysts and/or airspace filling and sarcoidosis (). 5 Alternatively, ILDs can also be classified based on disease behaviour into reversible (self-limited...
引用
- Thorax:Global perspective on pulmonary fibrosis: epidemiology, regional variations, gaps in care and future directions
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。